相关实验视频

Updated: Jan 7, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

在ALK阳性无塑性甲状腺癌的小鼠模型中,ALK抑制延长了生存期

Yara Maria Machlah¹, Tim Brandenburg¹, Georg Sebastian Hönes¹

¹Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Thyroid : official journal of the American Thyroid Association

|December 30, 2025

概括

无塑性甲状腺癌 (ATC) 随着无塑性淋巴瘤激酶 (ALK) 突变和p53损失而发展. 抗ALK抑制剂对治疗这种侵袭性癌症有前途.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

无塑性甲状腺癌 (ATC) 是一种高度攻击性的恶性瘤,治疗选择有限,预后不佳.
在ATC中,包括PI3K/MAPK/ERK通路激活和p53损失在内的遗传变化很常见.
形淋巴瘤激酶 (ALK) 基因的突变和重组与ATC的发展有关.

研究的目的:

研究ALK突变在ATC发展中的作用.
评估ALK抑制作为ATC治疗策略的疗效.
建立和描述一种用于研究ATC的新型小鼠模型.

主要方法:

产生了一种小鼠模型 (Trp53KO/ALKF1174L),具有可诱导的甲状腺细胞特异性突变ALK表达和p53删除.
从小鼠模型中建立了原发性甲状腺癌细胞系.
在体外和体内使用抑制剂TAE-684评估ALK抑制的影响.

主要成果:

Trp53KO/ALKF1174L小鼠发展出局部侵入性和转移性ATC,存活率降低.
抑制ALK降低了AKT/ERK酸化,并在ATC细胞中诱导了细胞毒性.
在小鼠模型中,TAE-684治疗显著延长了中位生存时间 (66天与18天对比).

结论:

ALK^F1174L突变和Trp53损失的结合推动了ATC的发展.
这项研究提供了第一个支持ALK抑制剂用于ALK驱动的ATC的功能性证据.
开发的小鼠模型和细胞系是ATC研究和治疗开发的宝贵工具.

关键词:

抑制了ALK的抑制.这是一种ALK突变.甲状腺癌的形性甲状腺癌.鼠标模型鼠标模型鼠标模型在 p53 里,p53 是一个 p53 的代码.

更多相关视频

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...